September 12, 2003
Ferring Pharmaceuticals, world pioneer and leader in industrial synthetic peptides, breaks ground for a new manufacturing site in Saint-Prex, canton of Vaud. The company will invest nearly EUR 90 million in the site construction and expects to employ approximately 250 people at the site by 2008.
The future for Ferring's new site begins today, when more than one hundred guests are scheduled to discover more about Ferring during a virtual tour at the 104,500 m2 site and attend the ground-breaking ceremony conducted by the Mayor of Saint-Prex, Günter Dauner and Ferring's Executive Chairman, Mr. Frederik Paulsen.
Ferring established its headquarters in Lausanne in 2000. The building of new production facilities in Switzerland continues Ferring's commitment to the region.
"I am very excited about this project. The new production site will allow us to meet a growing demand for our current products and secure the future supply of innovative new medicines that we have in development for our patients around the world", says Mr. Frederik Paulsen, son of Ferring's late founder Dr. Frederik Paulsen. He adds: 'We have been delighted with the warm reception we have received in Vaud and are grateful for the whole-hearted support we have from the community and the local government".
The building work starts this autumn, with expected completion by spring 2005 and commercial production planned for 2007. The completed building will cover 23,000 m2, including production, packaging and administration.
The design of the new building is the work of the Dolci Architecte / Tekne Management consortium in Yverdon-les-Bains and Lausanne. The 15m high building will make extensive use of natural daylight, both in the administration and production areas, through its use of glass walls as well as windows on the interior corridors.
"We chose Switzerland primarily due to the high concentration of quality personnel as well as its central location in Europe with easy access to transportation ... but the natural beauty of Saint-Prex was definitely a contributing factor", says Michel L. Pettigrew, Chief Operating Officer and adds: "Over the past years Ferring has shown a strong sales development. The new production site in Saint-Prex will make it possible for us to continue in this direction".
Michel L. Pettigrew represents Ferring at today's press conference at the Centre du Vieux-Moulin, Commune de Saint-Prex.
Ferring is a research driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynaecology, infertility and urology.
In recent years Ferring has expanded beyond its traditional European base and now has operating subsidiaries in over 40 countries.
To learn more about Ferring, please visit us at http://www.ferring.com
For additional information, please contact:
Ferring SA - Lausanne
+41 (0) 79 290 44 06
Mette Nikolajsen, Communication Officer
Ferring International Center - Copenhagen
+45 28 78 71 98